Jump to content

All Activity

This stream auto-updates

  1. Past hour
  2. I just answered this question. My Score PASS  
  3. I just answered this question. My Score PASS  
  4. Happy Birthday!🎂
  5. I just answered this question. My Score PASS  
  6. I just answered this question. My Score PASS  
  7. Today
  8. I just answered this question. My Score PASS  
  9. I just answered this question. My Score PASS  
  10. I just answered this question. My Score PASS  
  11. I just answered this question. My Score FAIL  
  12. Cliff started following Microscopes
  13. Microscopes This question and answer was originally published on Lab Tests Guide. They have generously permitted us to repost here on our site. This site's admin may have slightly modified the questions and answers. Please consider visiting their site: https://www.labtestsguide.com/ Submitter Cliff Category General Lab Submitted 07/11/2025  
  14. Cliff started following 2025-07-11 Birthdays
  15. Happy birthday
  16. PathLabTalk would like to wish all members celebrating their birthday today a happy birthday. Candybar (57)ribekak (49)Benh2s2s5 (47)sakee (45)jpuckett (44)vFabianDuncant (45)rilabtech (53)SheilaL (66)
  17. Hi - I’m curious to know how your facilities are implementing this revised CAP checklist TRM.31400 . Does your facility QC each of the panel cells on each day of use ? Thanks . TRM.31400 Antisera/Reagent Red Cell QC Phase II There are records of acceptable reactivity and specificity of typing sera and reagent red cells on each day of use, including a check against known positive and negative cells or antisera, or manufacturer's instructions for daily quality control are followed.
  18. Yesterday
  19. I just answered this question. My Score FAIL  
    • 0 downloads
    • Version 1.0.0
    Not for implementation. Contains non-binding recommendations. Docket Number: FDA-2024-D-1243 Issued by: Center for Biologics Evaluation and Research Allogeneic cells of human origin may be expanded in culture to manufacture medical products consisting of live cells, inactivated cells, cell lysates, or other cell-based materials such as cell-derived particles. We, FDA, are providing you, sponsors of allogeneic cell-based medical products, recommendations for determining the appropriate cell safety testing to support an Investigational New Drug Application (IND) or a Biologics License Application (BLA). Cell safety testing should be based on a risk analysis that considers the expansion potential of the cells, the reagents that are used to expand the cells in culture, and the number of individuals the cell-based medical product is capable of treating. This guidance supplements the following two final guidances: “Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry,” dated January 2020 , and “Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs),” dated April 2008.
  20. I just answered this question. My Score FAIL  
    • 0 downloads
    • Version 1.0.0
    Not for implementation. Contains non-binding recommendations. Docket Number: FDA-2024-D-4311 Issued by: Center for Biologics Evaluation and Research This guidance is intended to provide industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products and is intended to help facilitate the development of safe, effective, and high-quality CGT products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review, chemistry, manufacturing, and controls (CMC), pharmacology/toxicology (PT), clinical, and clinical pharmacology. In general, FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the FDA’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA’s guidances means that something is suggested or recommended, but not required.
  21. I just answered this question. My Score FAIL  
  22. I just answered this question. My Score FAIL  
  23. I just answered this question. My Score FAIL  
  24. I just answered this question. My Score FAIL  
  25. I just answered this question. My Score FAIL  
  26. I just answered this question. My Score FAIL  
  27. I just answered this question. My Score FAIL  
  28. Happy Birthday!🎂

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.